Tag: IMU

Immunge ASX IMU US Department Defense City Hope gastric cancer

Researchers to study Imugene’s cancer therapy following US Department of Defense grant

Immuno-oncology company Imugene’s (ASX: IMU) oncolytic virotherapy (OV) drug will receive a boost after City of Hope researchers received a US Department of Defense grant...
Imugene ASX IMU cancer vaccine tumour oncology

Imugene unveils swathe of positive data on cancer vaccine trials

Clinical stage immuno-oncology company Imugene (ASX: IMU) has presented a range of encouraging trial results on its cancer vaccine programs to thousands of top-level...
Imugene ASX IMU endpoints Phase 1b gastric cancer immuno-oncology trial HER-Vaxx vaccine

Imugene’s Phase 1b HER-Vaxx cancer trial meets endpoints, reports positive results

Clinical stage immuno-oncology company Imugene (ASX: IMU) has reported positive top-line results from a Phase 1b clinical study of its HER-Vaxx gastric cancer vaccine...
Imugene ASX IMU Phase 2 gastric cancer trial HER-Vaxx

Imugene receives timely tax rebate to assist ongoing gastric cancer trials

Immuno-oncology company Imugene (ASX: IMU) is set to move into the next phase of trials for its proprietary cancer vaccine, known as HER-Vaxx. The company...
Imugene ASX IMU HER-Vaxx clinical trials cancer vaccine

Imugene completes recruitment for HER-Vaxx clinical trials

Australian medical biotech company Imugene (ASX: IMU) has completed the recruitment of HER-2 gastric cancer patients for the Phase 1b clinical trial of its...
Imugene ASX IMU cancer vaccine positive results pre-clinical trials colorectal colon

Positive results in pre-clinical trials for Imugene’s cancer vaccine

Australian biopharmaceutical company Imugene (ASX: IMU) has reported “superior cancer growth inhibition” from a newly-acquired checkpoint inhibitor cancer vaccine, during preclinical trials with an...
Imugene ASX IMU captial raise cancer vaccine licence

Imugene to raise A$20.1m, secures cancer vaccine licence

Imugene (ASX: IMU) has received about A$12 million in commitments from institutional and sophisticated investors, as part of a A$20 million capital raising it...
Imugene ASX IMU arginine modulator drug candidate melanoma cancer

Imugene makes inroads into melanoma resistance via arginine drug candidate

Medical biotech company Imugene (ASX: IMU) has revealed that its clinical stage arginine modulator drug candidate has demonstrated “anti-tumour activity in 12 different cancer mouse...
Imugene ASX IMU mimotope cancer vaccine

Imugene readies ground-breaking mimotope cancer vaccine

Following 18 months of gruelling research, Imugene (ASX: IMU) has finally completed the early development of a new mimotope vaccine, aiming to treat a wide...
Imugene ASX IMU cancer vaccine gastric cancer trial

Imugene’s cancer vaccine yields promising results in gastric cancer trial

Immuno-oncology company Imugene (ASX: IMU) has yielded “promising” results while trialling its cancer vaccine in its gastric cancer clinical study. The HER-Vaxx cancer vaccine was...
Imugene Limited IMU ASX first patient dosing HER-Vaxx gastric cancer study

Imugene commences first patient dosing for HER-Vaxx gastric cancer study

Imugene Limited (ASX: IMU) has commenced first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer. Key Highlights: Imugene...